| CTRI Number |
CTRI/2025/08/092901 [Registered on: 12/08/2025] Trial Registered Prospectively |
| Last Modified On: |
28/06/2025 |
| Post Graduate Thesis |
No |
| Type of Trial |
BA/BE |
|
Type of Study
|
|
| Study Design |
Randomized, Crossover Trial |
|
Public Title of Study
|
An Open Label Single Dose Two Treatment Two Period Oral Bioavailability Study Comparing Apixaban 5 mg Oral Solution with Eliquis Apixaban 5 mg Film Coated Tablets In Healthy Adult Human Subjects Under Fasting Conditions |
|
Scientific Title of Study
|
An Open Label Balanced Randomized Single Dose Two Treatment Two Sequence Two Period Two Way Crossover Oral Bioavailability Study Comparing Apixaban 5 mg Oral Solution (1mg/ml) Manufactured by XL Laboratories Pvt Ltd 430 DLF Towers Shivaji Marg New Delhi 110015 India With Eliquis (Apixaban 5 mg Film Coated Tablets) Marketing Authorisation Holder Bristol Myers Squibb Pfizer Eeig Plaza 254 Blanchardstown Corporate Park 2 Dublin 15 D15 T867 Ireland In Healthy Adult Human Subjects Under Fasting Conditions |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| SLS-BE-0015-25-APIX Version: 01 Date: 08 Feb 25 |
Protocol Number |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Pradeep T |
| Designation |
Principal Investigator |
| Affiliation |
Spinos Lifescience and research private limited |
| Address |
Clinical Pharmacology unit Ground Floor No 29 A Krishna Maduravanam Vellakinar pirivuThudiyalur Coimbatore
Coimbatore
TAMIL NADU
641029
India |
| Phone |
08220586899 |
| Fax |
|
| Email |
pradeep.t@spinoslifescience.com |
|
Details of Contact Person
Scientific Query
|
| Name |
Dr Pradeep T |
| Designation |
Principal Investigator |
| Affiliation |
Spinos Lifescience and research private limited |
| Address |
Clinical Pharmacology unit Ground Floor No 29 A Krishna Maduravanam Vellakinar pirivuThudiyalur Coimbatore
TAMIL NADU
641029
India |
| Phone |
08220586899 |
| Fax |
|
| Email |
pradeep.t@spinoslifescience.com |
|
Details of Contact Person
Public Query
|
| Name |
Dr Pradeep T |
| Designation |
Principal Investigator |
| Affiliation |
Spinos Lifescience and research private limited |
| Address |
Clinical Pharmacology unit Ground Floor No 29 A Krishna Maduravanam Vellakinar pirivuThudiyalur Coimbatore
TAMIL NADU
641029
India |
| Phone |
08220586899 |
| Fax |
|
| Email |
pradeep.t@spinoslifescience.com |
|
|
Source of Monetary or Material Support
|
| Mahashiv Limited,
UK Unit 1,
Kataria Point,
1 Riches Road llford,
England- IG1 1JH
|
|
|
Primary Sponsor
|
| Name |
Mahashiv Limited |
| Address |
UK Unit 1,
Kataria Point,
1 Riches Road llford,
England- IG1 1JH
|
| Type of Sponsor |
Pharmaceutical industry-Global |
|
|
Details of Secondary Sponsor
|
| Name |
Address |
| Spinos Life Science and Research Private limited |
29 A Krishna Madhuravanam Vellakinar Pirivu Thudiyalur Coimbatore641029 Tamil Nadu India |
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Pradeep T |
Spinos Lifescience andResearch privatelimited |
Clinical Pharmacology unit GroundFloor No 29 A Krishna MaduravanamVellakinar pirivu ThudiyalurCoimbatore 641029
Coimbatore
TAMIL NADU
Coimbatore
TAMIL NADU |
08220586899
pradeep.t@spinoslifescience.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Research Ethics Committee RegistrationNoECR/84/Indt/TN/2013/RR-24 |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Healthy Human Volunteers |
Fasting Condition |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Apixaban 5 mg Oral Solution (1mg/ml) Manufactured by XL Laboratories Pvt Ltd, 430 DLF Towers, Shivaji Marg, New Delhi, 110015, India |
A Single oral dose Apixaban 5 mg Oral Solution (1mg/ml) will be administered ineach period Total Duration is 09 Days |
| Comparator Agent |
Eliquis (Apixaban 5 mg Film Coated Tablets) Marketing Authorisation Holder Bristol-/Myers Squibb/ Pfizer Eeig, Plaza 254, Blanchardstown Corporate Park 2, Dublin 15, D15 T867, Ireland |
A Single oral dose Eliquis (Apixaban 5 mg Film Coated Tablets) will be administered ineach period Total Duration is 09 Days |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
45.00 Year(s) |
| Gender |
Both |
| Details |
Normal healthy adult human subjects of age between 18 to 45 years and Body Mass Index (BMI) ranges between 18.50 kg/m2 to 30.00 kg/m2 according to the formula BMI weight (kg) height (m)2
Subjects who have no evidence of underlying disease during screening and check-in and whose screening is performed within 21 days of check in
Subjects whose screening laboratory values are within normal limits are considered by the physician or principal clinical investigator to be of no clinical significance
Healthy as documented by the medical history physical examination including but not limited to an evaluation of the cardiovascular gastrointestinal respiratory musculoskeletal and central nervous system and vital sign assessments
Generally healthy as documented by a 12 lead electrocardiogram ECG Chest X Ray and clinical laboratory assessments
Willing to consume Ovo lacto vegetarian diet
Willing to comply with all requirements of this study protocol as well as instructions from the study personnel
Non smokers
Generally healthy as documented by gynaecological examination and breast examination for female subjects period I only
Females of childbearing potential must have a negative serum pregnancy test performed within 21 days prior to the initiation of the study and a negative urine pregnancy test prior to check-in for each period
If the subject is female currently not pregnant not lactating or not attempting to become pregnant for 4 weeks before the screening visit throughout the duration of the study and 3 weeks after the subjects last study related visit for eligible subjects only if applicable has a negative serum pregnancy test and is of
non childbearing potential defined as
less than 1 year post menopausal no menstrual period for at least 12 consecutive months without any other medical cause
Surgically sterile bilateral tubal ligation bilateral oophorectomy or hysterectomy
or is of
childbearing potential willing to commit to using a consistent and acceptable method of birth control as defined below for the duration of the study
double barrier methods condoms cervical cap diaphragm and vaginal contraceptive film with spermicide
intrauterine device IUD with a low failure rate of less than 1% per year
or is of
childbearing potential and not sexually active willing to commit to using a consistent and acceptable method of birth control as defined above for the duration of the study in the event the subject becomes sexually active
|
|
| ExclusionCriteria |
| Details |
Evidence of allergy or known hypersensitivity to Apixaban or its inactive ingredients
Subjects with hepatic encephalopathy cholestasis myasthenia pre existing liver disease alcohol abuse existing tinnitus and pre existing gallbladder disease
Any major illness in the last three months or any significant ongoing chronic medical illness
Renal or liver impairment
Active bleeding or high risk for bleeding
Any disease or condition that might compromise the haemopoeitic gastrointestinal renal hepatic cardiovascular Musculoskeletal respiratory central nervous system or any other body system including presence of Diabetes Mellitus and Psychosis
History of alcohol addiction or abuse
Consumption of caffeine and or xanthine containing products i.e coffee tea chocolate caffeine containing sodas colas etc cigarettes and tobacco containing products for at least 48.00 hours prior to check-in and throughout the entire study
Consumption of alcohol and its products grapefruit and or its juice and poppy containing foods within 48.00 hours prior to clinic admission and throughout the entire study
Subjects who have taken any prescription medications within 14 days prior to study check-in and throughout the study and any over the counter medicinal products herbal medications within 07 days prior to study check-in and throughout the study
Subjects who have taken any unusual diet for whatever reason e.g. low salt for 48.00 hours prior to dosing and throughout the study
Subject who had participated in any other study within the 90 days of check-in
History of difficulty in swallowing
History of difficulty in accessibility of veins
Positive results for urine screen of drugs of abuse (Marijuana-THC, amphetamine AMP barbiturates BAR cocaine COC benzodiazepines BZD and morphine-MOR in urine prior to check-in of each period
Positive results for alcohol test prior to check-in of each period
Any blood donation excess blood loss within 90 days of check-in
Ingestion of any hormonal agent at any time within 14 days prior to the start of the study check-in
Use of hormone replacement therapy for a period of 06 months prior to dosing
Female subjects demonstrating a positive pregnancy screen
Female subjects who are currently lactating
Females are likely to become pregnant during the course of the study
|
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
Pharmacy-controlled Randomization |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
| To assess the Bioavailability of Apixaban 5 mg Oral Solution 1mg/ml Manufactured by XL Laboratories Pvt Ltd 430 DLF Towers Shivaji Marg New Delhi 110015 India with Eliquis (Apixaban 5 mg Film Coated Tablets) Marketing Authorisation Holder Bristol Myers Squibb Pfizer Eeig Plaza 254 Blanchardstown Corporate Park 2 Dublin 15 D15 T867 Ireland In Healthy Adult Human Subjects Under Fasting Conditions |
28 Time Points
00 00 hrs 00 08 hrs 00 16 hrs 00 25 hrs 00 33 hrs 00 42 hrs 00 50 hrs 00 75 hrs 01 00 hrs 01 33 hrs 01 67 hrs 02 00 hrs 02 33 hrs 02 67 hrs 03 00 hrs 03 33 hrs 03 67 hrs 04 00 hrs 04 33 hrs 04 67 hrs 05 00 hrs 05 50 hrs 06 00 hrs 08 00 hrs 10 00 hrs 24 00 hrs 48 00 hrs and 72 00 hrs |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| To monitor the safety and tolerability of test product comparing with the reference product in healthy adult human subjects under fasting conditions |
28 Time Points
00 00 hrs 00 08 hrs 00 16 hrs 00 25 hrs 00 33 hrs 00 42 hrs 00 50 hrs 00 75 hrs 01 00 hrs 01 33 hrs 01 67 hrs 02 00 hrs 02 33 hrs 02 67 hrs 03 00 hrs 03 33 hrs 03 67 hrs 04 00 hrs 04 33 hrs 04 67 hrs 05 00 hrs 05 50 hrs 06 00 hrs 08 00 hrs 10 00 hrs 24 00 hrs 48 00 hrs and 72 00 hrs |
|
|
Target Sample Size
|
Total Sample Size="32"
Sample Size from India="32"
Final Enrollment numbers achieved (Total)= "32"
Final Enrollment numbers achieved (India)="32" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
25/08/2025 |
| Date of Study Completion (India) |
08/10/2025 |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Date Missing |
|
Estimated Duration of Trial
|
Years="0"
Months="6"
Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Completed |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
At least 32 number of healthy, adult, human subjects will be
recruited to evaluate the Bioavailability of Test product with the Reference
product.
As per the discretion of the Investigator, a sufficient
number of stand-by subjects will be included additionally to ensure successful
dosing of 32 subjects in period I alone.
Note:
If needed the study will be conducted as batch wise
In each period, subjects will be housed in the clinical
facility for at least 11.00 hours pre-dose to 24.00 hours post-dose. A washout
period of at least 04 days will be maintained between each dosing period.
In each period, after an overnight fasting of at least 08.00
hours in the morning a single oral dose
of either the test product (T) or reference product (R) will be administered
(as per the randomization schedule) with 240 ml of drinking water
Blood pressure, radial pulse rate, body temperature, and wellbeing
status will be enquired and recorded at pre-dose 00.00 hour (within 75 minutes
of before dosing) and at 01.00, 02.00, 04.00, 06.00, 08.00 and 12.00 hours (±
60 minutes) post dose
Vitals will be recorded in bed side upto 04.00 hours of post
dose
Seated blood pressure, radial pulse rate, body temperature,
and wellbeing status will be enquired and recorded before the collection of the
ambulatory sample at 48.00 and 72.00 (±60 minutes) hours post-dose.
ECG will be recorded before check out (24.00 hours) for each
period and if any subject is withdrawn or dropped out during the study.
Monitoring for adverse events will be done
throughout the study period in clinical phase |